Amniotics AB (publ) (AMNI.ST)
Amniotics AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SE. The stock last traded at $0.01, up 5.88% on the session, giving a market capitalisation of $14.8M. Its beta of 0.53 implies it has historically moved less than the broad market.
Amniotics AB (publ) specializes in the creation, manufacturing, and commercialization of stem cell-based therapies, utilizing mesenchymal stem cells to address critical, life-threatening illnesses. The company's primary therapeutic candidate, PulmoStem, is designed for the treatment of inflammatory and fibrotic conditions affecting the lungs. Furthermore, Amniotics is advancing other promising treatments such as CogniStem for neurological disorders, NephroStem for kidney-specific ailments, and CutiStem for various dermatological issues. Beyond its own pipeline, the firm provides contract development and manufacturing services for advanced therapy medicinal products to pharmaceutical companies, universities, and hospitals. Established in 2015, Amniotics AB is headquartered in Lund, Sweden.
Amniotics AB (publ) is most often compared with the following Healthcare names: